RKT Reckitt Benckiser Group Plc

(Adds details)

By Tapan Panchal

LONDON--Shares of Indivior PLC (INDV.LN) is currently the biggest faller of the day on the FTSE250 Index after more U.S. states joined a lawsuit alleging anticompetitive practices.

At 1059 GMT Friday, shares in the company were trading 10.7% lower at 291 pence.

The maker of heroin addiction treatment drug Suboxone said in a short statement that 35 U.S. states and the District of Columbia have filed a civil complaint alleging violations of state and federal antitrust and consumer protection laws.

It said it will continue to vigorously defend its position.

Indivior, which was spun off from Reckitt Benckiser Group PLC (RB.LN) in 2014, is charged of conspiring with MonoSol Rx (MR1.BE) to convert the market from Suboxone tablets to Suboxone films that melt in the mouth to prevent or delay generic alternative drugs, after the company lost its orphan drug exclusivity in 2009.

The Suboxone drug generates the majority of the company's annual revenue. The U.S. Food and Drug Administration first approved the tablet form of the drug in 2002 as an orphan drug for treatment of opioid dependence.

The film version of Suboxone was approved and launched in 2010.

Write to Tapan Panchal at tapan.panchal@wsj.com

(END) Dow Jones Newswires

September 23, 2016 07:49 ET (11:49 GMT)

Reckitt Benckiser (LSE:RKT)
Historical Stock Chart
From Mar 2024 to Apr 2024

Reckitt Benckiser (LSE:RKT)
Historical Stock Chart
From Apr 2023 to Apr 2024